AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
| Revenue (TTM) | $552.16M |
| Gross Profit (TTM) | $417.46M |
| EBITDA | $17.75M |
| Operating Margin | 0.37% |
| Return on Equity | -0.97% |
| Return on Assets | -0.30% |
| Revenue/Share (TTM) | $11.51 |
| Book Value | $9.71 |
| Price-to-Book | 2.97 |
| Price-to-Sales (TTM) | 2.60 |
| EV/Revenue | 2.509 |
| EV/EBITDA | 59.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 14.30% |
| Shares Outstanding | $50.64M |
| Float | $48.55M |
| % Insiders | 3.85% |
| % Institutions | 102.36% |
Volatility is currently contracting